EVEREST MED (01952) and Haisen have entered into a strategic cooperation framework agreement.

EVEREST MED (01952) announced that on September 9, 2026, the subsidiary (a wholly-owned subsidiary of the company) entered into a strategic cooperation framework agreement with Haisen. Both parties agreed to establish a framework for the supply, distribution, and related manufacturing and commercialization of products in China. The Group has been developing its pharmaceutical distribution and supply chain capabilities in China and expects to obtain a pharmaceutical business license in the country by the end of 2026. Upon obtaining the relevant license, the Group intends to conduct pharmaceutical business and distribution activities in accordance with applicable GSP requirements. In this regard, the Group plans to leverage the strategic cooperation framework agreement with Haisen (as its partner) to utilize its GSP platform, commercial infrastructure, and production-related resources, as well as various products owned or authorized by the Haisen Group, to jointly expand commercial services, distribution, and production-related cooperation for products in the region. The Group has been developing its pharmaceutical distribution and supply chain capabilities in China and expects to obtain a "Pharmaceutical Business License" (i.e., a government-issued pharmaceutical distribution license) by the end of 2026. Upon obtaining the relevant license, the Group intends to conduct pharmaceutical business and distribution activities for its own pipeline products (including but not limited to Enfuvirtide, Viread, and Etravirine) in accordance with applicable GSP requirements. Furthermore, considering the Group's employees, facilities, and other resources in production and commercialization, as well as the products owned by Haisen, the strategic cooperation framework agreement is expected to enable the Group to utilize its existing capabilities on a larger scale and provide support for the efficient supply, distribution, and commercialization of products in China. The amounts payable to the Haisen Group under the strategic cooperation framework agreement primarily relate to the procurement costs of products or materials associated with the Group's downstream distribution, sales, and commercialization activities, and will form part of the Group's operating cost base, rather than an independent service fee payable to the Haisen Group. The Board believes that the strategic cooperation framework agreement will further enable the Group to leverage its supply chain, manufacturing, and commercialization infrastructure, expand its revenue base, and deepen its strategic collaboration with Haisen.